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Abstract
Induced pluripotent stem cells (iPSCs) are novel stem cells derived from adult mouse and human tissues by reprogramming.
Elucidation of mechanisms and exploration of efficient methods for their differentiation to functional cardiomyocytes are
essential for developing cardiac cell models and future regenerative therapies. We previously established a novel mouse
embryonic stem cell (ESC) and iPSC differentiation system in which cardiovascular cells can be systematically induced from
Flk1
+ common progenitor cells, and identified highly cardiogenic progenitors as Flk1
+/CXCR4
+/VE-cadherin
2 (FCV) cells. We
have also reported that cyclosporin-A (CSA) drastically increases FCV progenitor and cardiomyocyte induction from mouse
ESCs. Here, we combined these technologies and extended them to mouse and human iPSCs. Co-culture of purified mouse
iPSC-derived Flk1
+ cells with OP9 stroma cells induced cardiomyocyte differentiation whilst addition of CSA to Flk1
+ cells
dramatically increased both cardiomyocyte and FCV progenitor cell differentiation. Spontaneously beating colonies were
obtained from human iPSCs by co-culture with END-2 visceral endoderm-like cells. Appearance of beating colonies from
human iPSCs was increased approximately 4.3 times by addition of CSA at mesoderm stage. CSA-expanded human iPSC-
derived cardiomyocytes showed various cardiac marker expressions, synchronized calcium transients, cardiomyocyte-like
action potentials, pharmacological reactions, and ultra-structural features as cardiomyocytes. These results provide a
technological basis to obtain functional cardiomyocytes from iPSCs.
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Introduction
Induced pluripotent stem cells (iPSCs) are novel pluripotent
stem cells generated from adult tissues by reprogramming
originally with transduction of a few defined transcription factors,
such as Oct4, Sox2, Klf4, and c-myc [1], [2]. Establishment of
iPSC lines from adult human tissue is facilitating development of
cell transplantation-based regenerative strategies and establish-
ment of patient-derived cells as disease models. Efficient
differentiation and dissecting the differentiation mechanisms of
target cells would significantly contribute to elucidate the
pathophysiology of diseases and provide a platform for developing
new therapeutic strategies for specific diseases through such as
drug discovery [3], [4].
Cardiomyocytes are a major target of regenerative medicine.
Although cardiomyocyte differentiation has been reported from
various progenitor and adult cell sources (e.g. bone marrow,
cardiac biopsies, adipose tissue, umbilical cord, mesenchymal cells,
etc), overall, the efficiencies of functional cardiomyocyte appear-
ance have been still variable (,1–5%) [5]. Pluripotent cells,
embryonic stem cells (ESCs) and iPSCs have thus emerged as
among the most promising stem cell sources for inducing
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purification methods have been reported, starting with either
mouse or human ESCs. These include stem cell aggregation in
suspension and growth as embryoid bodies (EBs), co-culture with
stroma cells, serum-free culture in differentiation medium, or
hypoxic culture [6], [7], [8], [9], [10], [11]. Overall, the efficiency
of cardiomycyte differentiation in human ESCs [6] should be still
lower than in mouse ESCs [8], [11]. In view of the similarities
between iPSCs and ESCs, most cardiomyocyte induction methods
from iPSCs are based on those tried and tested in ESCs. Several
groups have thus reported cardiomyocyte formation from mouse
iPSCs using either EBs or stroma cell co-culture [12], [13], [14].
Recently, several reports on cardiomyocyte induction from human
iPSCs appeared with based on EB formation though the
efficiencies are still varied [15], [16], [17], [18], [19]. Other new
methods robust in human iPSCs remain to be explored and maybe
of particular value for preparation of transplantation cell sources
as well as dissecting the differentiation mechanisms and drug
discovery.
Previously, we developed a novel ESC differentiation system
that recapitulates early cardiovascular development in vivo [8],
[20], [21]. Flk1 (also known as vascular endothelial growth factor
(VEGF) receptor-2) is the earliest differentiation marker for
endothelial cells (ECs) and blood cells, and is a marker of lateral
plate mesoderm [21], [22]. We induced Flk1
+ cells from ESCs,
purified them by fluorescence-activated cell sorting (FACS), and
re-cultured the purified cells. We succeeded in inducing the major
cardiovascular cell types from the common Flk1
+ progenitor cells:
vascular ECs, mural cells (pericytes and vascular smooth muscle
cells) [20] and cardiomyocytes [8]. When purified Flk1
+ cells were
cultured on mouse bone marrow-derived stromal cells, OP9 cells,
spontaneously beating cardiomyocytes as well as ECs can be
induced within 3–4 days (Flk-d3-4) even from a single cell. We,
thus, demonstrated that ESC-derived Flk1
+ cells serve as
cardiovascular progenitors [8], [20], [23], which was further
supported with following several mouse and human studies [9],
[24], [25], [26]. We also identified a Flk1
+/CXCR4
+/vascular
endothelial cadherin
2 (FCV) population as highly cardiogenic
progenitor cells among the progeny of Flk1
+ mesoderm cells at the
single cell level [8]. That is, in an intermediate stage of ESC
differentiation between Flk1
+ mesoderm cells and cardiomyocytes
(Flk-d2), purified FCV population could efficiently give rise to
cardiomyocytes from a single cell. The cardiogenic potential of
FCV cells was 15–20 times higher than that of other cell
populations among the Flk1
+ cell progeny. We further confirmed
FCV cells can differentiate into cardiomyocytes in vivo through
cell transplantation experiments [11]. FCV cells, which are
detected just 1–2 days before the cardiomyocyte appearance, are
so far the nearest upstream cardiac progenitors to cardiomyocytes.
This system proved amenable to induce various cardiovascular
cells systematically from ESCs, explore novel differentiation
methods, and dissect the differentiation processes [23], [27],
[28]. Indeed, we recently succeeded in demonstrating that an
immunosuppressant, cyclosporin-A (CSA) showed a novel potent
effect specifically on Flk1
+ mesoderm cells to induce a dramatic
increase in FCV cardiac progenitor cells and cardiomyocytes with
the use of this ESC differentiation system [11]. That is, when CSA
was added to Flk1
+ cells co-cultured on OP9 cells, appearance of
FCV progenitor cells and cardiomyocytes were increased by 10–
20 times.
Recently, we were able to systematically induce cardiovascular
cells from mouse iPSCs in a way almost identical to that using
mouse ESCs [12]. Here, we combined our technologies in ESCs
and iPSCs and showed that FCV cardiac progenitors and
cardiomyocytes were efficiently expanded from mouse iPSCs by
CSA treatment. Moreover, we extended the CSA method to
human iPSCs and showed that CSA also successfully worked in
human iPSC differentiation and efficiently enhanced the appear-
ance of spontaneously beating cells. Human iPSC-derived
cardiomyocytes showed expected molecular, structural and
functional features of human cardiomyocytes. We, thus, succeeded
in inducing and enhancing cardiac cell differentiation from both
mouse and human iPSCs.
Methods
Antibodies
Monoclonal antibodies (MoAbs) for murine E-cadhein
(ECCD2), murine Flk1 (AVAS12) were prepared and labeled in
our laboratory as described previously [8], [21], [29]. MoAb for
cardiac troponin-T (cTnT) (1:2000) was purchased from Neo-
Markers (Fremont, CA). For staining human ESCs and iPSCs,
another MoAb for cTnT (1:100) was from Santa Cruz
Biotechnology (Santa Cruz, CA). MoAbs for murine and human
a-actinin (1:800) was from Sigma (St Louis, Mo). MoAb of
phycoerithrin (PE)-conjugated AVAS12 was purchased from
eBioscience (San Diego, CA). MoAbs for biotinylated-CXCR4
was purchased from BD Pharmingen (San Diego, CA). Anti-
HCN4 (1:200) and anti-Cav3.2 (1:200) antibodies were from
Chemicon (Temecula, CA). Anti-Kir2.1 (1:200) and anti-connexin
43 (1:200) antibodies were from Alomone (Israel) and Invitrogen
(Carlsbad, CA), respectively.
Reagents
Cyclosporin-A (a gift from Novartis Pharma) was dissolved in
Dimethyl sulfoxide (DMSO) (Nacalai Tesque, Kyoto Japan) at
30 mg/mL. Dilution of 1–3 mg/mL were made in differentiation
medium at the time of use. PKH67 fluorescent dye was purchased
from Sigma (St. Louis, MO).
Mouse iPSC culture
A germline-competent mouse iPSC line, 20D-17, carrying
Nanog promoter-driven GFP/IRES/puromycin resistant gene
(Nanog-iPS cells), was maintained as previously described [30].
Briefly, iPSCs were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) containing 15% FCS, non-essential amino
acids, 1 mmol/L sodium pyruvate, 5.5 mmol/L 2-mercaptoetha-
nol, 50 units/mL penicillin and 50 mg/mL streptomycin on
feeder layers of mitomycin-C-treated mouse embryonic fibroblast
(MEF) cells carrying stably incorporated puromycin-resistance
gene. OP9 stroma cells were maintained as described [21].
Induction of mouse cardiomyocyte differentiation
Induction of Flk1
+ cells and sorting for Flk1
+ cells were
performed as previously described [8], [12], [20]. Briefly, mouse
iPSCs were first plated on to gelatin-coated dishes and cultured for
30 min to eliminate attached feeder cells, then, non-adherent cells
were collected and induced to differentiation. Mouse iPSCs were
cultured at a density of 1–2.5610
3 cells/cm
2 in differentiation
medium (DM)(alpha minimum essential medium (GIBCO, Grand
Island, NY) supplemented with 10% fetal calf serum) on type IV
collagen-coated dishes (Biocoat, Beckton Dickinson) or mitomycin
C-treated confluent OP9 cell sheets (MMC-OP9) for 96–108 h.
Cells were collected and selected by FACS to purify Flk1
+ cells.
Flk1
+ cells were then plated on to MMC-OP9 at a density of 1–
10610
3 cells/cm
2 and cultured in differentiation medium to
induce cardiac differentiation. CSA (1–3 mg/mL) was added to
Flk1
+ cells on OP9 cells. Medium was replaced every 2 days.
Cardiac Cells from Mouse and Human iPS Cells
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16734Figure 1. Cardiac cell expansion from mouse iPSC-derived Flk1
+ mesoderm by CSA. A. Gross appearance of cardiomyocyte induction by
CSA. Six days after the Flk1
+ cell culture on OP9 cells (Flk-d6). cTnT staining (brown). Left panel: control. Right panel: CSA treatment. Scale
bars=400 mm. B. Quantitative evaluation of cardiomyocyte induction by fluorescent intensity of cTnT staining. Relative fluorescent intensity is
Cardiac Cells from Mouse and Human iPS Cells
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FACS for differentiating mouse iPSCs was performed as
described previously [8], [12], [20]. After 96–108 h of iPSC
differentiation, cultured cells were harvested and stained with
allophycocyanin (APC)-conjugated AVAS12 and FITC-conjugat-
ed ECCD2. Viable Flk1
+/E-cadherin
2 cells, excluding propidium
iodide (Sigma), were sorted by FACS AriaII (Becton Dickinson).
For FACS for FCV progenitor cells, after 2 days differentiation of
purified Flk1
+ cell on PKH67-stained OP9 cells (Flk-d2), cultured
cells were harvested and stained with a combination of MoAbs of
PE-conjugated AVAS12 and biotinylated CXCR4 followed by
addition of streptoavidin-conjugated APC, and subjected to FACS
analysis. PKH-negative populations were analyzed and sorted as
iPSC-derived cells. The Flk1
+/CXCR4
+ population (which was
vascular endothelial cadherin-negative) [8] was designated ‘‘FCV
cells’’. For FACS for cardiomyocytes, cells were harvested after 6–
8 days culture of Flk1
+ cells on OP9 cells (Flk-d6-8). Induced
cardiomyocytes were selected using tetramethyl rhodamine methyl
ester (TMRM) (Invitrogen) [12], a fluorescent probe to monitor
the membrane potential of mitochondria. In brief, cells were
dissociated with 0.25% tryprin/EDTA, then incubated in DM
with 50 nmol/L TMRM at 37uC for 15 minutes. Stained cells
were washed twice and selected by FACS. TMRM-high
population was considered as purified cardiomyocytes in iPSCs.
Human iPSC culture
END-2 cells were cultured as described previously [31]. Human
iPS cell lines induced with transduction of four transcription
factors (Oct4, Sox2, Klf4, and c-myc), 201B6 and 201B7, and
Myc-negative human iPSC lines, 253G1 and 253G4 were
maintained as previously described [1], [32]. 253G1 was used as
the human iPS cell representative in all experiments unless stated
otherwise. Induction of cardiomyocyte differentiation from human
iPSCs was performed by co-culturing clumps of undifferentiated
human iPSCs on END-2 cells, essentially as described previously
[31]. To study the effect of CSA on cardiomyocyte differentiation,
3 mg/mL CSA was added to the culture medium on day 0 (END2-
d0) or 8 (END2-d8) after start of co-culture. The number of
beating colonies on END2-d12 was scored by microscopic
examination. For intracellular Ca
++ measurement and immuno-
staining for cTnT and actinin, beating colonies were mechanically
excised, then gently dissociated by trypsin-EDTA treatment (at
37uC, 10 min), and replated on to gelatin-coated dishes. For
electrophysiological analysis, beating colonies were mechanically
excised and then dissociated by trypsin-EDTA with DNAse I (at
37uC, 10–15 min), and replated on to gelatin-coated dishes.
Immunohistochemistry
Immunostaining of murine cardiomyocytes was performed as
described [8], [11], [12]. Briefly, 4% paraformaldehyde (PFA)-
fixed cells were blocked by 2% skimmed milk (BD, bioscience) and
incubated with 1st Abs. For immunohistochemistry, anti-mouse
IgG –horse radish peroxidase (HRP) (Invitrogen) was used as 2nd
Abs. For immunofluorescent staining, anti-mouse, rat and rabbit
immunoglobulin conjugated with Alexa 488 or 546 were used for
2nd Abs. Nuclei were visualized with DAPI (Invitrogen).
Cardiomyocyte differentiation was quantified as the fluorescent
intensity of cTnT staining as described [8]. Immunostaining for
human cardiomyocytes, 4% paraformaldehyde (PFA)-fixed cells
were processed with 0.2% Triton X100 and 1% BSA (Sigma), and
incubated with 1st Abs. Stained cells were photographed with
inverted fluorescent microscopy, Eclipse TE2000-U (Nikon,
Tokyo, Japan), digital camera system, AxioCam HRc (Carl Zeiss,
Germany), or BIOREVO BZ-9000 (Keyence, Osaka, Japan).
Electrophysiology
Membrane potentials of single cells within a beating colony
were measured using whole-cell patch clamp electrophysiology in
the current-clamp mode (Axopatch200B, Axon Instruments/
Molecular Devices Corp., Union City, CA). All recordings were
carried out at room temperature [8].
Buffer compositions. Bath solution contained (in mmol/L)
140 NaCl, 5.4 KCl, 0.33 NaH2PO4, 0.45 MgCl2, 1.8 CaCl2, and 5
HEPES (pH=7.4 with NaOH). Pipette solution contained (in
mmol/L) 110 L-Aspartic acid, 30 KCl, 5 MgATP, 0.1 NaGTP, 5
K2Creatine phosphate, 2 EGTA, 10 HEPES, and 10 NaOH
(pH=7.2 with KOH).
Field potential (FP) recordings of the beating colonies were
performed using The MED64 multi-electrode array (MEA) system
(Alpha MED Scientific Inc., Osaka, Japan) at a sampling rate of
20 kHz with low path filter of 500 Hz or high path filter of 1 Hz.
All MEA measurements were performed at 37uC with heated
perfusion system. The signals were recorded and processed with
the Mobius software (WitXerx, US). The medium were perfused
1.7 ml/min as 37uC, and then the FPs were recorded for 5 min.
Subsequently, E-4031(Calbiochem, US), isoproterenol (Proternol-
LH, Kowa Pharmaceutical Company, Tokyo, Japan), or propran-
prol (InderalH, AstraZeneca, Japan) was added to medium
(discrete colony samples were used for each drug). Then, the
FPs were measured for about 10 min.
Intracellular Ca measurement
Human iPSCs were loaded with 4 mM Quest Fluo-8 (ABD
Bioquest, Inc. Sunnyvale, CA) for 30 min. Fluo-8 fluorescence
(excitation at 495610 nm and emission at 535620 nm) of beating
colony was measured every 16 msec with a back-thinned electron
multiplier CCD camera (ImagEM; Hamamatsu Photonics,
Hamamatsu, Japan). Four consecutive images were averaged.
Ratio (F1/F0) to an image at minimum fluorescence intensity (F0)
was calculated after background subtraction. The measurements
were carried out at room temperature.
Reverse Transcription Polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated from various kinds of cell populations
with the use of RNeasy Mini Kit (QIAGEN, Valencia, CA). cDNA
was synthesized by the SuperScript III First-strand Synthesis
System (Invitrogen). Polymerase chain reaction was performed
with the use of KOD Plus (Toyobo, Tokyo, Japan) as described
[33]. Primer sequences [34] are shown in Table S1.
indicated (n=4, {,p ,0.001 vs control). C. Representative action potential of iPSC-derived spontaneously beating cardiomyocytes. D. Sarcomeric
organization in TMRM-purified cardiomyocytes at Flk-d8. Immunostaining with anti-sarcomeric a-actinin antibody (red) and DAPI (blue). Right panel
shows higher magnification of boxed area. Scale bar=25 mm. E–H. Double immunostaining of TMRM-purified cardiomyocytes at Flk-d8 for
connexin43 (Cx43) (green) and cTnT (orange) (E), Cav3.2 (green) and cTnT (orange) (F), HCN4 (green) and cTnT (orange) (G), Kir2.1 (green) and cTnT
(orange) (H). Nuclei are visualized with DAPI. Scale bars=25 mm. I. FACS analysis for cardiac progenitor induction from mouse iPSCs by CSA. X axis:
CXCR4. Y axis: Flk1. Percentages of FCV cardiac progenitor cells (double positive population; red boxes) in total Flk1
+ cell progenies are indicated.
doi:10.1371/journal.pone.0016734.g001
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16734Figure 2. Induction and expansion of cardiomyocytes from human iPSCs. Human iPSCs were co-cultured with END-2 cells to differentiate
cardiomyocytes. A. Gross morphology of a beating colony from human iPSCs (captured photo from Movie S1). B. cTnT staining of a beating colony
on END-2 cells. Left panel: phase contrast image. Right panel: human cTnT staining (green). Scale bar =50 mm. C. RT-PCR analysis for differentiation
markers during cardiomyocyte differentiation of human iPSCs (from END2-d0 to d12). Oct3/4: Undifferentiated cell marker, Brachyury-T:
mesendoderm marker, KDR (human Flk1): mesoderm marker, Islet1: mesoderm and cardiac progenitor marker, Nkx2.5: cardiac progenitor and
cardiomyocyte marker, cTnT: cardiomyocyte marker. D. Representative gross appearance of human iPSC-derived beating colonies at END2-d12 in 12-
well dishes. Left panels: control. Right panels: CSA treatment from END2-d8. Upper panels: phase contrast images. Beating colonies are shown by red
arrows. Lower panels: cTnT staining (green). E–G Quantitative evaluation of beating colony appearance. E. Total colony count (control; 17769.7/well
(12-well dishes)(n=8), CSA; 16268.0/well (n=9); N.S., p=0.237), F. Beating colony count (control; 9.161.2/well (12-well dishes)(n=8), CSA; 36.462.5/
well (n=9); {,p ,0.0001), and G. Percentages of beating colonies (control; 5.460.9% (n=8), CSA; 23.562.8% (n=9); {,p ,0.0001) in total colonies
that appeared at END2-d12. H. Immunostaining of actinin (red) and DAPI (blue) in dissociated cardiomyocyte colonies. The same colony is shown in
Movie S2. Right panel shows higher magnification of boxed area. Sarcomere structures are evident. Scale bar=50 mm.
doi:10.1371/journal.pone.0016734.g002
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Human iPSC-derived beating colony was replated on multi-well
chamber slide (NUNC Rochester, NewYork), fixed with 2%
glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.4) for 30–
60 min, washed and immersed with phosphate buffered saline for
overnight at 4uC, and fixed in 1% buffered osmium tetroxide. The
specimens were then dehydrated through graded ethanol and
embedded in epoxy resin. Ultrathin sections (90 nm), double-
stained with uranyl acetate and lead citrate, were examined under
electron microscopy (H-7650; Hitachi, Tokyo, Japan).
Statistical Analysis
All data were obtained from at least three independent
experiments. Statistical analysis of the data was performed using
Student’s t-test or ANOVA. p,0.05 was considered significant.
All data are shown as mean 6 S.D.
Results
Cardiomyocyte and cardiac progenitor expansion from
mouse iPSCs by CSA
Recently, we reported that functional cardiomyocytes were
induced from mouse iPSCs with our differentiation method in
mouse ES cells [12]. In brief, undifferentiated mouse iPSC
colonies maintained on MEFs were morphologically similar to
mouse ESCs. We induced mesoderm differentiation from mouse
iPSCs by culturing on type IV collagen-coated dish with DM (see
Methods). Flk1
+ mesoderm cells that appeared were selected by
FACS at 4.5 days of differentiation (iPS-d4.5) and then underwent
a cardiomyocyte induction protocol involving co-culture on OP9
stroma cells; spontaneously beating cardiomyocytes began to
appear after 3 to 4 days of culture (Flk-d3-4). Beating cells that
appeared were positive for multiple cardiomyocyte markers and
had electrophysological features assessed by whole-cell patch
clamp as previously reported [8], [12].
In the present study, we first tried to expand cardiomyocytes
and cardiac progenitors from mouse iPS cells by CSA. When CSA
was added to purified Flk1
+ cells, the appearance of cTnT
+
cardiomyocytes was increased 12-fold compared to controls
(Fig. 1A, B), which was comparable with the increase observed
in mouse ESCs [11]. CSA-expanded cardiomyocytes spontane-
ously beat and showed cardiomyocyte-like action potential
(average interval: 0.74 sec, maximum diastolic potential:
258.6 mV and overshoot: 34.3 mV (n=6)) (Fig. 1C). These
cardiomyocytes also showed distinct sarcomere formation
(Fig. 1D), expression of cTnT (Fig. 1E-H) and connexin 43
located at cellular boundaries (Fig. 1E). T-type calcium channel
Cav3.2 (Fig. 1F), a pacemaker ion channel, HCN4 (Fig. 1G), and a
ventricular ion channel, kir2.1 (Fig. 1H) were also detected in
cTnT
+ cells. We also examined the effect of CSA on the induction
of FCV cardiac progenitor cells in mouse iPSCs. Addition of CSA
to Flk1
+ cells specifically increased the FCV population in mouse
iPSCs to approximately 6.5 times of control. The maximum
percentage of FCV cells within total Flk1
+ cell-derived cells was
more than 30% by CSA (Fig. 1I), comparable with that observed
in mouse ESCs, previously [11]. CSA can thus efficiently enhance
the differentiation of functional cardiomyocytes and cardiac
progenitors from mouse iPSCs.
Differentiation of cardiomyocytes from human iPSCs
We next examined cardiomyocyte differentiation from human
iPSCs. We employed a human ESC differentiation method for
cardiomyocytes using END-2 visceral endodermal stroma cells
[31]. When human iPSCs were cultured on END-2 cells,
spontaneously beating cardiomyocytes were successfully induced
(Fig. 2A, Movie S1). Beating colonies were first detected after
END2-d10 and became maximally evident after END2-d12.
Figure 3. Functional analysis of expanded human cardiomyo-
cytes. A. Ca
++ transient in dissociated beating colonies. Cytoplasmic
Ca
++ change was monitored with fluo-8. Left panel: a transmission
image of fluo-8 loaded iPSC colony. Middle and right panels: Fluo-8
images at the end (a) and the peak (b) of the fluorescence change. Scale
bar=50 mm. Lower panel: Time course of fluo-8 intensity change. The
intensity was measured at the periphery (1), the entire colony (2) and
the center (3) (ROIs shown in middle panel). Ratios (F1/F0) of the
intensity to the one at the beginning of recording (F0) are indicated.
Note that Ca transient is well synchronized within the colony. Real time
video is shown in Movie S3. B. Representative action potential recorded
from a cell in a beating colony. C. Representative single whole cell
patch-cramp recording of a non-self beating human iPSC-derived
cardiomyocyte after electrical stimulation.
doi:10.1371/journal.pone.0016734.g003
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the differentiation of human iPSCs on END2 cells, sequential
expression of various marker genes expected for cardiomyogenesis
was observed (ex: Oct3/4; undifferentiated iPSCs, Brachyury;
mesendoderm, KDR; mesoderm, islet1; mesoderm and cardiac
progenitors, nkx2.5; cardiac progenitors and cardiomyocytes,
cTnT; cardiomyocytes) (Fig. 2C). In our another previous study
on human ESC differentiation, a Flk1 (in human, VEGF receptor-
2)
+/TRA1-60
2 mesoderm population appeared in culture ap-
proximately 8 days after induction of differentiation [35]. When
CSA was added to differentiating human iPSCs at the mesoderm
stage (i.e. on END2-d8), the appearance of beating colonies was
increased (Fig. 2D) although no effect was observed with the CSA
treatment on undifferentiated human iPSCs (i.e. from END2-d0)
(data not shown). Whereas the total number of iPSC-derived
colonies that appeared was not changed (Fig. 2E), the number and
percentage of beating colonies that appeared at END2-d12 were
significantly increased approximately 4.0 and 4.3 times by CSA
treatment, respectively (Fig. 2F, G). Approximately 2362.7% of
total colonies was beating in average, and in an optimized
condition, 39% of total colonies included beating cardiomyocytes.
CSA-expanded colonies maintained self-beating after a mechan-
ical isolation and re-plating, and were positive for a-actinin with
distinct sarcomere formation (Fig. 2H, Movie S2). Thus,
cardiomyocyte induction from human iPSCs could be similarly
enhanced by CSA. The mesoderm stage-specific effect of CSA
in human iPSCs suggests the similar machinery in mouse ES/
iPSCs are robustly working in human iPSC differentiation to
cardiomyocytes.
Functional features of expanded human iPSC-derived
cardiomyocytes
We next evaluated functional features of CSA-expanded human
iPSC-derived cardiomyocytes. Fluo-8 imaging revealed synchro-
nized increases in intracellular Ca
++ in beating colonies with
contraction (Fig. 3A, Movie S3). Action potentials recorded by
patch clamp electrophysiology identified cells with pacemaker
potential (average of the interval: 4.26 sec, maximum diastolic
potential: 267.6 mV overshoot: 46.6 mV (n=6))(Fig. 3B). Re-
plated colonies continued beating spontaneously for more than 10
months. Some isolated single cells obtained from beating colonies
at 3 months culture period lost automaticity and showed some
features of human ventricular cells such as action potential with
rapid depolarization and prolonged plateau after electrical
stimulation (Fig. 3C). These results indicate that various functional
human cardiomyocytes could be induced in this system.
We further examined pharmacological reactions of CSA-
expanded human cardiomyocytes to show the relevance as cardiac
cell models. We recorded field potential of re-plated beating
colonies with multi-electrode array under simulation of a b-
stimulant, isoproterenol, a b-blocker, propranorol, and a HERG
channel inhibitor, E-4031. Addition of isoproterenol significantly
increased the beating frequency (Fig. 4A), on the other hand,
propranorol significantly decreased the beating frequency (Fig. 4B).
E-4031 dose-dependently prolonged the length of time from the
first negative peak to first positive peak, which is corresponding to
QT time in electrocardiogram (Fig. 4C). These results indicate
that CSA-expanded human iPSC-derived cardiomyocytes can
suffice multiple functional features as human cardiomyocyte cell
models.
Ultra structural features of expanded human iPSC-
derived cardiomyocytes
We finally confirmed features of CSA-expanded human iPSC-
derived cardiomyocytes at the ultrastructural level using electron
microscopy. Beating colonies induced from human iPSCs
resembled native cardiomyocytes, showing myofibrillar bundles
with transverse Z-bands and enriched mitochondria (Fig. 5A-D).
Other cardiomyocyte-specific structures, such as intercalated disks
with desmosomes (Fig. 5D), atrial secretory granule-like structures
(Fig. 5E), and glycogen granules (Fig. 5F) were also observed.
Together, these results indicate that bona fide human cardiomy-
ocytes can be successfully induced and expanded from human
iPSCs with this method.
Discussion
Here we demonstrated the induction and expansion of cardiac
progenitors and functional cardiomyocytes from iPSCs using
potent and specific effect of CSA. Human cardiomyocytes with
multiple expected structural and functional features could be
induced with this method. This method provides a critical
technological basis to obtain cardiac cells from human iPSCs.
We have demonstrated previously that CSA treatment is most
effective in inducing FCV cardiac progenitor cells, the nearest
upstream of cardiomyocytes in mouse ESCs [11]. Here we showed
that CSA effects on FCV cardiac progenitor and cardiomyocyte
induction were also completely reproduced in mouse iPSCs.
Moreover, CSA also showed significant enhancing effects of
cardiomyocyte differentiation from human iPSCs in the END-2
system. This is the first report to show the effect of CSA in human
stem cells. In this study, we examined four human iPSC clones,
201B6, B7 (induced with four factors) [1], 253G1 and G4 (induced
without c-myc) [32]. Though the basal efficiency of cardiomyocyte
differentiation from 201B6, B7 and 253G4 were lower than that
from 253G1, CSA treatment significantly enhanced cardiomyo-
cyte appearance similarly in all these human iPSC clones (Figure
S1). Thus, CSA robustly induced cardiogenic differentiation in
mouse ESCs, iPSCs and human iPSCs regardless their species and
derivation methods.
The molecular mechanisms conducting this potent CSA effect
on cardiac lineage is important, but still it is unknown. Though we
examined another calcineurin inhibitor, FK506, and a NF-AT
inhibitor, 11R-VIVIT, both of them did not reproduce the effect
of CSA [11], indicating that the cardiogenic CSA effect is
mediated by other molecular target than immunosuppressing
effect of CSA. Further elucidation of molecular mechanisms of
CSA in cardiomyocyte differentiation would be critical for the
exploration of cardiomyocyte differentiation and regeneration
strategies.
CSA-expanded cardiomyocytes from human iPSCs exhibited
many features sufficing as functional cardiomyocytes. Cardiomy-
ocytes with pacemaker-like or ventricular-like action potentials
were successfully induced. Nevertheless, they were still immature
compared with mature adult cardiomyocytes [36], [37] and they
Figure 4. Pharmacological responses of human iPSC-derived cardiomyocytes. Field potential recordings of replated beating colonies after
stimulation with isoproterenol (A), propranorol (B), and E-4031 (C). Photos; array of multi-electrode and replated colonies. Data recorded at
electrodes in red squares are shown. A, B. Beating frequency (beating/minite). C. QT elongation. The time period from the first negative peak (open
triangle) to the first positive peaks (closed triangles) reflects QT time in electrocardiogram. n=3, {,p ,0.001.
doi:10.1371/journal.pone.0016734.g004
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such as relatively low global electron density, sparse myofibrils,
and abundant ribosome granules (Fig. 5). Methods for further
maturation as well as specific induction and purification of the
various cardiac cell types (pacemaker, atrial, ventricular, conduc-
tion system cells etc.) should be explored in future study.
Interestingly, a recent clinical report showed that CSA
prevented cardiac reperfusion injury by protecting cardiomyocytes
from apoptosis [38]. Cardiogenic effects of CSA in later stages of
differentiation of human iPSCs imply that CSA may positively
affect on endogenous cardiac progenitors to induce cardiac
regeneration in patients. Though it is still unknown whether
endogenous cardiac regeneration can be induced by CSA
administration, our study may offer a scientific basis to support
a clinical opportunity for CSA as a cardiac regenerative drug.
This novel cardiac cell differentiation method for iPSCs would
thus broadly contribute to cardiac regenerative medicine by
providing various options for cell preparation, transplantation
strategies, and drug discovery.
Supporting Information
Figure S1 Quantitative evaluation of beating colony
appearance in iPSC clones. 201B6 cells: Total colony count
(control; 20366.4/well (12-well dishes)(n=3), CSA; 19364.0/well
(n=3); N.S., p=0.0915), beating colony count (control; 4.061.0/
well (n=3), CSA; 13.763.5/well (n=3); *, p,0.05), percentages
of beating colonies (control; 2.060.5% (n=3), CSA; 7.161.7%
(n=3); **, p,0.01) in total colonies that appeared at END2-d12.
201B7 cells: Total colony count (control; 20468.3/well (n=3),
Figure 5. Ultrastructural analysis of human iPSC-derived cardiomyocytes. Transmission electron microscopic images of beating colonies.
Myofibrils with Z-bands (white closed arrowheads in A–D.), mitochondria (black closed arrowheads in B–D.), intercalated disk-like structure with
desmosome (white open arrow in D.), atrial sercetory granules (electron-dense granules surrounded by double membranes. White open arrowheads
in A. and E. (magnified image of A.)), glycogen granules (electron-dense small granules. Black open arrowheads in D. and F. (magnified image of
D.)), ribosomal granules (electron-lucent small granules. White arrows in B–D. and G. (magnified image of B.)). N: nucleus. Scale bar =2 mm, direct
magnify, 63000 (A), 67000 (B), 64000 (C), 65000 (D).
doi:10.1371/journal.pone.0016734.g005
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(control; 5.061.0/well (n=3), CSA; 18.363.1/well (n=3);
**, p,0.01), percentages of beating colonies (control; 2.560.6%
(n=3), CSA; 9.261.5% (n=3); **, p,0.01). 253G4 cells: Total
colony count (control; 20164.0/well (n=3), CSA; 20163.8/well
(n=3); N.S., p=0.9216), beating colony count (control; 4.760.6/
well (n=3), CSA; 15.061.0/well (n=3); **, p,0.05), percentages
of beating colonies (control; 2.360.3% (n=3), CSA; 7.560.6%
(n=3); {,p ,0.001)
(TIF)
Movie S1 A beating colony induced from human iPS
cells at END2-d12 (Fig. 2A).
(MOV)
Movie S2 A dissociated beating colony induced from
human iPS cells on END-2 cells (Fig. 2H).
(MOV)
Movie S3 Real time monitoring of Ca
++ transient by
Fluo-8 in dissociated beating colony induced from
human iPS cells (Fig. 3A). Clear and synchronized Ca
++
transient is observed.
(MOV)
Table S1 Primers for PCR.
(RTF)
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